← Back
Neogenomics
NEO · listed on Nasdaq · worth $2.55 billion
$16.59
−3.07% today
No insider bought Neogenomics stock in the last year. They sold it 2 times, $527.7K in all. One member of Congress reported trading Neogenomics in the last year.
Red dot = an insider soldA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
117.0M shares
90% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, two insiders sold Neogenomics stock and none bought. None of the 2 sales is marked on its filing as planned in advance; all by company executives. The biggest seller was Warren Stone, Pres & Chief Operating Officer.
Planned sales
Form 144 notices filed for Neogenomics in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Executive Greg D. Aunan filed to sell 20,000 shares on 4 Aug; no sale reported yetNotice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Neogenomics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.First Trust Portfolios LP7.8%Jul 30
US Congress
Members of Congress who reported trading Neogenomics in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for Neogenomics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Nov 28, 2025SoldAlicia C. OlivoNov 28, 2025 · Traded Nov 25, 2025 · EVP, GC & Business Development20,916 @ $12.00$251K
Oct 20, 2025SoldAlicia C. OlivoOct 20, 2025 · Traded Oct 16, 2025 · EVP, GC & Business Development4,918 @ $10.00$49.2K
Aug 6, 2025BoughtJeffrey Scott ShermanAug 6, 2025 · Chief Financial Officer+11%20,000 @ $5.62$112.3K
1 more with Pro →Analysts, earnings and news
Analysts' price target
$15.11 average
9 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
4 of 4 quarters above
Q1 '26$0.01 a share+$0.01
Q4 '25$0.06 a share+$0.02
Q3 '25$0.03 a share+$0.01
Q2 '25$0.03 a share+$0.01